RBR-25rtydq进行中（未招募）3 期
Tocilizumab role in reducing the complications of COVID patients - TOCIPAK Tocilizumab in Pakistan
ady Reading Hospital-MTI Peshawar0 个研究点开始时间: 2021年8月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 17Y 至 0（—）
入选标准
- •Confirmed or suspected SARS-CoV infection; Adult patient; Moderate to Critical COVID Patients
排除标准
- •Known hypersensitivity to Tocilizumab or its excipients; patient below 18 years; mild cases of Confirmed or suspected SARS-CoV
研究者
相似试验
尚未招募
3 期
The use of tocilizumab in patients with severe COVID 19 pneumonia - a trial to know its efficacy in those on steroidsCTRI/2020/12/029793aveen Naik B
进行中（未招募）
1 期
A clinical trial with the aim to explore the efficacy and safety of adding tocilizumab to standard of care in patients withearly rheumatoid arthAdult Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-006040-79-DKAarhus University Hospital, Department of Rheumatology180
已完成
不适用
Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000007845Department of Cardiovascular Medicine Graduate School of Medicine Osaka University15
尚未招募
不适用
Role of Tocilizumab in COVID-19 Pneumonia patientsCTRI/2020/08/027246GCS Medical College Hospital and Research Centre
已完成
不适用
ong-term Safety of treatment with tocilizumab in the refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000025943Osaka Unversity9